Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

16.98 -0.73 (-4.09%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
How Do Investors Really Feel About Teva Pharmaceutical Indus?
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Where Teva Pharmaceutical Indus Stands With Analysts
Via Benzinga
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base. 
Via Benzinga
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Interest Rates Political
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
Via The Motley Fool
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Why Teva Pharmaceutical Stock Is Soaring Today
Via The Motley Fool
Topics Earnings Stocks
Exposures Financial US Equities
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations. 
Via Benzinga
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report
Teva stock jumped early Wednesday after the drugmaker hiked its 2025 profit outlook, though trimmed its sales forecast. 
Via Investor's Business Daily
Topics Government
Exposures Political
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.